ARTV earnings analysis
What we found in ARTV's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Artiva Biotherapeutics reported a Q1 2026 net loss of $23.5 million, up from a loss of $20.3 million in Q1 2025, with EPS of -$0.95. The company remains without revenue, focusing on clinical development with positive updates on AlloNK trials, supported by cash reserves expected to last until Q2 2027.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Increased Net Loss YoY
- Net loss for Q1 2026 was $23.5 million, compared to $20.3 million in Q1 2025.
- No Revenue Yet Again
- Artiva reported no revenue again for Q1 2026, same as prior periods.
- Positive Clinical Data Announced
- Positive preliminary results for AlloNK were highlighted with a 71% ACR50 response.
- Extended Cash Runway
- Cash reserves of $86.8 million are expected to last until Q2 2027.
- Increased R&D Expense
- R&D expenses rose to $19.3 million in Q1 2026 from $17.1 million in Q1 2025.
- Regulatory Designations Received
- Received Fast Track designation for AlloNK for refractory RA in January 2023.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continued Losses
- The company posted an operating loss of $24.4 million, increasing financial strain.
- No Revenue Generation
- Artiva has not generated any revenue since inception, raising sustainability concerns.
- Patent and Licensing Risks
- Dependence on licenses with GC Cell risks loss of rights if obligations are not met.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.95
What they said about what is next.
Management deferred revenue guidance as focus remains on clinical stage development.
The filing reads about the same as the one before it.
What came before.
- 10-K · April 30, 2026
- Artiva Biotherapeutics, Inc. reported no revenue for the fiscal year ending December 31, 2025, continuing its clinical-stage focus on NK cell therapy, specifically AlloNK for refractory rheumatoid arthritis. The company…
- 10-K · March 10, 2026
- Artiva remains a clinical-stage NK cell therapy company prioritizing AlloNK for refractory rheumatoid arthritis, citing Fast Track designations and planned FDA interactions in H1 2026. Financially the company reported…
- 10-Q · November 12, 2025
- Artiva reported no revenue for the quarter and a larger GAAP net loss versus prior-year quarter: a net loss of $21,528 (three months ended September 30, 2025) versus $17,472 in Q3 2024, while EPS modestly improved to…
- 10-K · March 24, 2025
- Artiva (ARTV) is an early-stage, clinical-stage cell therapy company focused on an allogeneic, off‑the‑shelf NK cell product (AlloNK) for autoimmune diseases and cancers. The 10‑K emphasizes manufacturing-first strategy…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ARTV makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever